# Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)

> **NCT07729397** · PHASE1 · NOT_YET_RECRUITING · sponsor: **The Methodist Hospital Research Institute** · enrollment: 21 (estimated)

## Conditions studied

- Diffuse Large B-Cell Lymphoma (DLBCL)
- Hodgkin Lymphoma
- Peripheral T-cell Lymphoma (PTCL)
- Anaplastic Large Cell Lymphoma, ALK-Positive
- Anaplastic Large Cell Lymphoma, ALK-Negative

## Interventions

- **BIOLOGICAL:** Autologous C7R.CD30-CAR-EBVSTs

## Key facts

- **NCT ID:** NCT07729397
- **Lead sponsor:** The Methodist Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-01-15
- **Primary completion:** 2030-03-31
- **Final completion:** 2044-02-28
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2026-07-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07729397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07729397, "Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07729397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*